-
1
-
-
0033611522
-
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
-
Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
-
(1999)
N Engl J Med
, vol.340
, pp. 265-271
-
-
Turrisi, A.T.1
Kim, K.2
Blum, R.3
-
2
-
-
0032880527
-
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma
-
Bonner JA, Sloan JA, Shanahan ThG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999;17:2681-91.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2681-2691
-
-
Bonner, J.A.1
Sloan, J.A.2
Shanahan, Th.G.3
-
3
-
-
0032858243
-
Phase II study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer
-
Furuse K, Fukuoka M, Kawahara M, et al. Phase II study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer. J Clin Oncol 1999;17:2692-9.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2692-2699
-
-
Furuse, K.1
Fukuoka, M.2
Kawahara, M.3
-
4
-
-
0029865811
-
Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non small cell lung cancer: A randomized study
-
Jeremic B, Shibamato Y, Acimovic L Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non small cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1065-1070
-
-
Jeremic, B.1
Shibamato, Y.2
Acimovic, L.3
Milisavljevic, S.4
-
5
-
-
0033762484
-
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agent
-
Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agent. Drugs 2000;60(Suppl 1):1-14.
-
(2000)
Drugs
, vol.60
, Issue.1 SUPPL.
, pp. 1-14
-
-
Rowinsky, E.K.1
-
6
-
-
0346369500
-
Angiogenesis and metastasis growth (written in consultation with Judah Folkman)
-
Angiogenesis and metastasis growth (written in consultation with Judah Folkman) [editorial]. Advances in Oncology 1996;12:2-7.
-
(1996)
Advances in Oncology
, vol.12
, pp. 2-7
-
-
-
7
-
-
0035863288
-
Vascular endotelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival and postoperative relapse in non-small cell lung cancer
-
Yuan A, Yu CH-J, Kuo S-H, et al. Vascular endotelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival and postoperative relapse in non-small cell lung cancer. J Clin Oncol 2001;19:441-3.
-
(2001)
J Clin Oncol
, vol.19
, pp. 441-443
-
-
Yuan, A.1
Yu, C.H.-J.2
Kuo, S.-H.3
-
8
-
-
0033731630
-
Relationship between vessel density and expression of vascular endotelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro
-
Lund EL, Thorsen CH, Pedersen MWB, Junker N, Kristjansen PEG. Relationship between vessel density and expression of vascular endotelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Clin Cancer Res 2000;6:4287-91.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4287-4291
-
-
Lund, E.L.1
Thorsen, C.H.2
Pedersen, M.W.B.3
Junker, N.4
Kristjansen, P.E.G.5
-
10
-
-
0033760493
-
Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer
-
Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-8.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3944-3948
-
-
Passlick, B.1
Sienel, W.2
Seen-Hibler, R.3
-
11
-
-
85030081970
-
An overview of key compounds from the BMS oncology pipeline: Matrix metalloproteinase inhibitor BMS-275291 and epothilone analog BMS-187550
-
Madrid: Bristol-Myers, S.A.
-
Birkhofer M. An overview of key compounds from the BMS oncology pipeline: matrix metalloproteinase inhibitor BMS-275291 and epothilone analog BMS-187550. Encuentros en Oncología (Segovia, 5-6 de abril de 2001). Madrid: Bristol-Myers, S.A., 2001; p. 33-5.
-
(2001)
Encuentros en Oncología (Segovia, 5-6 de Abril de 2001)
, pp. 33-35
-
-
Birkhofer, M.1
-
12
-
-
85030081529
-
Oncofarmacogenómica. Nuevos conceptos en los ensayos clínicos
-
abril 5-6; Segovia
-
Díaz Rubio E. Oncofarmacogenómica. Nuevos conceptos en los ensayos clínicos. Encuentros en Oncología; 2001, abril 5-6; Segovia.
-
(2001)
Encuentros en Oncología
-
-
Díaz Rubio, E.1
-
13
-
-
0012755255
-
Translation of the biology of lung cancer to targeted therapies
-
mayo 12-15; San Francisco
-
st Annual Meeting; 2001, mayo 12-15; San Francisco; 395, 406.
-
(2001)
st Annual Meeting
, pp. 395
-
-
Bunn, P.1
-
15
-
-
0000397265
-
A randomized phase II trial comparing Rhumab VEGF plus carboplatin and paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
-
De Vore KF, Fehrenbacher L, Herbst RS, et al. A randomized phase II trial comparing Rhumab VEGF plus carboplatin and paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am. Soc Clin Oncol 2000;19:485.
-
(2000)
Proc Am. Soc Clin Oncol
, vol.19
, pp. 485
-
-
De Vore, K.F.1
Fehrenbacher, L.2
Herbst, R.S.3
-
16
-
-
0001834442
-
Randomized double-blind placebo controlled trial of marimastat in patients with small cell lung cancer following response to first line chemotherapy: An NCI-CTG and EORTC study
-
Shepherd FA, Giaccone G, Debruyne C, et al. Randomized double-blind placebo controlled trial of marimastat in patients with small cell lung cancer following response to first line chemotherapy: an NCI-CTG and EORTC study. Proc Am Soc Clin Oncol 2001;20:4.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 4
-
-
Shepherd, F.A.1
Giaccone, G.2
Debruyne, C.3
-
17
-
-
0001185393
-
Phase III study of the matrix metalloproteinase (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer
-
Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloproteinase (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:307.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 307
-
-
Smylie, M.1
Mercier, R.2
Aboulafia, D.3
-
19
-
-
84880483191
-
Epidermal growth factor receptor blockade as anticancer therapy
-
mayo 12-15; San Francisco
-
st Annual Meeting. 2001, mayo 12-15; San Francisco; 39-41.
-
(2001)
st Annual Meeting
, pp. 39-41
-
-
Mendelsohn, J.1
-
20
-
-
0033757709
-
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
-
Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000;60(Suppl 1):15-23.
-
(2000)
Drugs
, vol.60
, Issue.1 SUPPL.
, pp. 15-23
-
-
Raymond, E.1
Faivre, S.2
Armand, J.P.3
-
21
-
-
0034332542
-
New therapeutic agents targeting the epidermal growth factor receptor
-
Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000;18(Suppl):S54-9.
-
(2000)
J Clin Oncol
, vol.18
, Issue.SUPPL.
-
-
Baselga, J.1
-
22
-
-
0033757346
-
Epidermal growth factor receptor Tyrosine Kinase inhibitors as anticancer agents
-
Ciardello F. Epidermal growth factor receptor Tyrosine Kinase inhibitors as anticancer agents. Drugs 2000;60(Suppl 1):25-32.
-
(2000)
Drugs
, vol.60
, Issue.1 SUPPL.
, pp. 25-32
-
-
Ciardello, F.1
-
23
-
-
0033763084
-
ZD1839 ("Iressa") as an anticancer agent
-
Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs 2000;60(Suppl 1):33-40.
-
(2000)
Drugs
, vol.60
, Issue.1 SUPPL.
, pp. 33-40
-
-
Baselga, J.1
Averbuch, S.D.2
-
24
-
-
0000004189
-
A phase I intermittent dose-escalation trial of ZD1839 in Japanese Patients with solid malignant tumours
-
Nakagawa K, Yamamoto N, Kudoh S, et al. A phase I intermittent dose-escalation trial of ZD1839 in Japanese Patients with solid malignant tumours. Proc Am Soc Clin Oncol 2000;19:183.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
, pp. 183
-
-
Nakagawa, K.1
Yamamoto, N.2
Kudoh, S.3
-
25
-
-
0000240853
-
Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-TKI) in patients with five selected tumor types: Evidence of activity and good tolerability
-
Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-TKI) in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am. Soc Clin Oncol 2000;19:177.
-
(2000)
Proc Am. Soc Clin Oncol
, vol.19
, pp. 177
-
-
Baselga, J.1
Herbst, R.2
LoRusso, P.3
-
26
-
-
0002200965
-
Intermittent oral ZD1389, a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study
-
Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD1389, a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study. Proc Am Soc Clin Oncol 2000;19:3.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
, pp. 3
-
-
Ferry, D.1
Hammond, L.2
Ranson, M.3
-
27
-
-
0000329007
-
A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-base chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer
-
Pérez Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-base chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:310.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 310
-
-
Pérez Soler, R.1
Chachoua, A.2
Huberman, M.3
-
28
-
-
0000940657
-
Randomized phase II trial of Trastuzumab plus either Docetaxel or Paclitaxel in previously untreated advanced non-small cell lung cancer
-
Krug LM, Miller VA, Crapanzano J, et al. Randomized phase II trial of Trastuzumab plus either Docetaxel or Paclitaxel in previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:333.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 333
-
-
Krug, L.M.1
Miller, V.A.2
Crapanzano, J.3
-
29
-
-
0035810145
-
Targeting the BCR-ABL Tyrosine Kinase in chronic myeloid leukemia
-
Targeting the BCR-ABL Tyrosine Kinase in chronic myeloid leukemia [editorial]. N Engl J Med 2001;344:1084-6.
-
(2001)
N Engl J Med
, vol.344
, pp. 1084-1086
-
-
-
30
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
Druker BJ, Talpaz M, Resta DR, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
-
(2001)
N Engl J Med
, vol.344
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.R.3
-
31
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
-
(2001)
N Engl J Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
-
32
-
-
0035810148
-
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
-
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
-
(2001)
N Engl J Med
, vol.344
, pp. 1052-1056
-
-
Joensuu, H.1
Roberts, P.J.2
Sarlomo-Rikala, M.3
-
33
-
-
0033883653
-
The Selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
-
Krystal GW, Honsawek S, Litz J, Buchdunger E. The Selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3319-3326
-
-
Krystal, G.W.1
Honsawek, S.2
Litz, J.3
Buchdunger, E.4
-
34
-
-
0003236113
-
Dose escalation of oral Farnesyl transferase inhibitor (FTI) BMS-214682 in patients with solid tumors
-
Camacho LH, Soignet SL, Pezzulli S, et al. Dose escalation of oral Farnesyl transferase inhibitor (FTI) BMS-214682 in patients with solid tumors. Proc Am. Soc Clin Oncol 2001;20:79.
-
(2001)
Proc Am. Soc Clin Oncol
, vol.20
, pp. 79
-
-
Camacho, L.H.1
Soignet, S.L.2
Pezzulli, S.3
-
35
-
-
0000005997
-
Phase I study of Farnesyl transferase inhibitor, BMS-214662 in solid tumors
-
Kim KB, Shin DM, Summey CC, et al. Phase I study of Farnesyl transferase inhibitor, BMS-214662 in solid tumors. Proc Am Soc Clin Oncol 2001;20:79.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 79
-
-
Kim, K.B.1
Shin, D.M.2
Summey, C.C.3
-
36
-
-
0001252683
-
A phase I study of the Farnesyl transferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients with advanced solid tumors: Clinical findings
-
Voi M, Tabernero J, Cooper MR, et al. A phase I study of the Farnesyl transferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients with advanced solid tumors: clinical findings. Proc Am Soc Clin Oncol 2001;20:79.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 79
-
-
Voi, M.1
Tabernero, J.2
Cooper, M.R.3
-
37
-
-
0003334694
-
A phase I dose escalating study of BMS-214662 with cisplatin in patients with advanced solid tumors
-
Mackay HJ, Hoekstra R, Eskens F, et al. A phase I dose escalating study of BMS-214662 with cisplatin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:80.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 80
-
-
Mackay, H.J.1
Hoekstra, R.2
Eskens, F.3
-
38
-
-
0000023012
-
A phase I pharmacokinetic and pharmacodynamic study of the Farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies
-
Nakagawa K, Yamamoto N, Nishio K, et al. A phase I pharmacokinetic and pharmacodynamic study of the Farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies. Proc Am Soc Clin Oncol 2001;20:80.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 80
-
-
Nakagawa, K.1
Yamamoto, N.2
Nishio, K.3
-
39
-
-
0000165438
-
A phase I, clinical and pharmacokinetic trial of the Farnesyl transferase inhibitor (FTI) R115777 + Docetaxel: A promising combination in patients with solid tumors
-
Piccart-Gebhart MJ, Branle F, De Valerola D, et al. A phase I, clinical and pharmacokinetic trial of the Farnesyl transferase inhibitor (FTI) R115777 + Docetaxel: a promising combination in patients with solid tumors. Proc Am Soc Clin Oncol 2001;20:80.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 80
-
-
Piccart-Gebhart, M.J.1
Branle, F.2
De Valerola, D.3
-
40
-
-
0000318295
-
Enhanced myelosuppression of Topotecan when combined with the Farnesyl transferase inhibitor, R115777: A phase I & pharmacodynamic study
-
Liebes L, Hochster H, Speyer J, et al. Enhanced myelosuppression of Topotecan when combined with the Farnesyl transferase inhibitor, R115777: a phase I & pharmacodynamic study. Proc Am Soc Clin Oncol 2001;20:81.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 81
-
-
Liebes, L.1
Hochster, H.2
Speyer, J.3
-
41
-
-
0000814480
-
A phase I trial of the Farnesyl transferase inhibitor, R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer
-
Adjer AA, Erlichman C, Marks RS, et al. A phase I trial of the Farnesyl transferase inhibitor, R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer. Proc Am Soc Clin Oncol 2001;20:81.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 81
-
-
Adjer, A.A.1
Erlichman, C.2
Marks, R.S.3
-
42
-
-
0000262572
-
Phase I/II trial of ISIS 3521, an antisense inhibitir of PKC-alpha, with Carboplatin and Paclitaxel in non-small cell lung cancer
-
Fisher G, Advani R, Moore M, et al. Phase I/II trial of ISIS 3521, an antisense inhibitir of PKC-alpha, with Carboplatin and Paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:309.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 309
-
-
Fisher, G.1
Advani, R.2
Moore, M.3
|